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Abstract: The vast majority of cutaneous squamous cell carcinoma (CSCC) will occur in those with fair complexion, tendency to burn, 
and high ultraviolet radiation (UVR) exposure. Organ transplant recipients also are an important population at great risk for CSCC. An 
association has been reported between oral contraceptive (OC) use, human papillomavirus virus (HPV) and cervical cancer, and there 
could be a similar association for CSCC. The cutaneous HPV β-E6 protein, a close cousin of the transformative E6 protein underlying 
anogenital cancers, has been shown to inhibit apoptosis in response to UVR damage and stimulate morphologic transformation in rodent 
fibroblast cell lines. Furthermore, OC use has been shown to enhance HPV transcription and may contribute to CSCC risk through this 
pathway.
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1. Introduction
Cutaneous squamous cell carcinoma (CSCC) is the 
second most common malignancy among Caucasians 
in the United States (US).1,2 Often locally aggressive 
and resulting in substantial morbidity, this cancer 
rarely spreads distally.3,4 However, while the overall 
5-year metastatic rate is #5%, lesions of the lip and 
ear are particularly aggressive, with metastasis rates 
approaching 20%.5–7
CSCC occurs more commonly among iatrogeni-
cally immunosuppressed patients, and the potential 
for metastasis also is greater in this population.7–12 
In immunosuppressed organ transplant recipi-
ents (OTR), lesions occur primarily in chronically 
 sun-exposed skin,13,14 typically are histologically 
deeper at time of diagnosis,13 increase in incidence 
with duration of immunosuppressive therapy,15 and 
are characterized by a 4:1 reversed squamous-to-basal 
cell type (ie, basal cell skin cancer is the predominate 
type in immunocompetent patients).16 Human papil-
lomavirus virus (HPV) DNA is detected in approxi-
mately 75% of CSCCs from OTRs, compared with 
47% in non-immunosuppressed patients,17 and is 
thought to be a factor in the etiology of these cancers.6 
Also, high metastatic rates have been reported for 
radiation-induced CSCCs of the face and neck18 and 
for CSCCs arising in patients infected with human 
immunodeficiency virus (HIV);19,20 rates are com-
parable to those of squamous cell carcinoma (SCC) 
of the cervical and anal tracts in immunosuppressed 
patients.21
CSCC is observed more frequently in Caucasians 
than African-Americans (AA), Asians, or  Hispanics.22 
Among AA, CSCCs are commonly located on the 
lower extremities and have a reversed squamous 
cell-to-basal cell ratio resembling that of immuno-
suppressed OTRs.22–26 The lesions often arise from 
scars, burns, and ulcers and tend to be histologically 
invasive.24,26–29 Approximately 29% of AA with CSCC 
develop regional lymph node metastasis and succumb 
to the disease.27 CSCC is paradoxically rare in AA and 
Asian OTRs,15,30 possibly reflecting  differences in the 
ethnic distribution of HLA B27 and HLA A11,31–33 the 
former predisposing and the latter conferring resis-
tance to skin tumors.34
The associations of CSCC with ultraviolet radia-
tion (UVR)35,36 and innate pigmetary factors such 
as fair complexion (eg, propensity to burn on  initial 
exposure; inability to tan on repeated exposure),37–41 
light-colored eyes, and red hair37,38,40–44 are well 
established. Chronic exposure to UVR is known 
to induce immunosuppression45–48 and to promote 
skin carcinogenesis.49–53 Sunlight does not play a 
significant etiologic role in CSCC among African-
Americans, since most lesions present on covered 
areas.24,27,54–56 The effect of cumulative lifetime sun 
exposure on CSCC is greatly diminished after adjust-
ment for  pigmentary factors.37
The greater frequency of CSCC than basal cell 
skin cancer (BCSC) on the upper limbs suggests that 
UVR exposure alone does not fully explain risk for 
CSCC.57 This also is indicated by the substantially 
lower incidence of CSCC among Hawaiian Cauca-
sians than Australian Caucasians.58 Other factors 
associated with CSCC include ionizing radiation/
radon,18,59–67 certain chemical compounds,22,68,69 iat-
rogenic immunosuppression,11,70,71 physical trauma 
(burns and scars),68,72,73 human papillomavirus 
virus,17,74–78 higher education,42,59,79,80 and genetic pre-
disposition (xeroderma pigmentosa, epidermoplasia 
verruciformis).68 Latent intervals of 40 or more years 
suggest that the risk of cancer in irradiated skin per-
sists for the life of the person, and raise the possibility 
of long latencies for other short-term exposures in the 
etiology of CSCC.18
An increase in the incidence of CSCC over time 
has been reported in several longitudinal studies.81–87 
The increase may reflect lifestyle changes such as 
increased voluntary exposure to UVR (eg, frequent 
use of tanning salons, increased outdoor recreational 
activity, tendency to wear less sun protective clothing, 
mid-winter vacations in sunny locations), increased 
sexual activity resulting in exposure to HPV, and/or 
greater life expectancy. The depletion of the ozone-
layer also may be a contributing factor.88–90 A 1% per-
cent reduction in stratospheric ozone is estimated to 
increase the incidence of nonmelanoma skin cancer 
(NMSC) between 3% and 6%.88,91
Understanding exposures that predispose individu-
als to CSCC is especially important since individuals 
with this cancer may be more likely to develop and 
die from certain secondary malignancies.92–116 In the 
paper, we briefly examine the potential role of OC use 
on cancer risk in general and then specifically address 
the plausibility of OC use as a risk factor for CSCC, 
as suggested by recent epidemiologic studies.42,117 
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Next, we summarize the supportive evidence link-
ing HPV infection with cancer and CSCC, focusing 
on the transmission route for HPV. In conclusion, 
we examine the combine effect of OC use and HPV 
infection on increased CSCC risk and present a con-
ceptual model underlying the putative association 
(Fig. 1). Both OC use and HPV infection are prevent-
able exposures, and the latter is a suitable target for 
vaccination if implemented prior to infection.118
2. Methods
2.1 Search strategy
To identify papers on CSCC, OC use, and HPV, 
a comprehensive literature search was conducted 
using the Medline/PubMed database from inception 
to December 2010. We also examined the references 
of the papers identified electronically, and searched 
for unpublished studies, PhD dissertations, inter-
nal reports, and conference proceedings/abstracts. 
Finally, to include those studies in which OC use or 
HPV infection was a secondary factor, we checked 
the tables of every article that examined risk factors 
for CSCC.
2.2 Inclusion criteria
Studies were included only if the target popula-
tion, outcome and exposures of interest were clearly 
defined and results were based on valid statistical 
methods with evaluation of errors and discussion of 
study bias. Studies in which participants were cho-
sen at convenience were not considered. Priority was 
given to papers that presented original data rather 
than reviews or meta-analyses.
3. Association between OC Use  
and Cancer
Data from animal studies and tissue samples indi-
cate that estrogen (a key ingredient in oral contra-
ceptive pills) is genotoxic, induces carcinogenic 
effects, and increases the proliferation of certain 
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Figure 1. Conceptual model depicting the association between OCs, HPv and CSCC.
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cancer cells.119–121 Subcutaneous administration of 
oestradiol in mice increases the incidence of mammary, 
pituitary, uterine, cervical, vaginal, lymphoid, and 
testicular tumors.122 In contrast, high doses of oestra-
diol significantly reduce (P , 0.05) the incidence of 
cervical squamous cell carcinomas induced in mice 
with 3-methylcholanthrene (MCA).122 The use of 
combined OCs (co-administration of an estrogen and 
a progestogen) has been classified as carcinogenic 
to humans by the International Agency for Research 
on Cancer (IARC).121 However, the evidence linking 
OC use with cancer in humans is neither consistent 
nor definitive.121,123–125 For example, OC use appears 
to promote cancers at some sites (eg, triple-negative 
breast cancer126), while affording protection at other 
sites (eg, endometrial cancer127).
3.1 Cutaneous squamous cell carcinoma
The epidemiology of CSCC has been difficult to study 
because few cancer registries record this cancer on a 
routine basis. Furthermore, CSCC and BCSC, which 
are biologically and histologically distinct cancers 
with different clinical characteristics, often are stud-
ied under the general heading of NMSC.
An analysis of self-reported skin cancers,  excluding 
CM, in the Oxford Family Planning Association 
(Oxford-FRA) contraceptive study did not observe 
a greater risk for these cancers among OC users 
(ever used, RR = 0.9, 95% CI = 0.6–1.4; recently used, 
RR = 0.4, 95% CI = 0.1–1.2; used in past, RR = 1.0, 
95% CI = 0.6–1.6) than hospitalized referrents who 
had never used oral contraceptives.128 However, the 
findings from this study are difficult to evaluate since 
cases were self-reported and the comparison group 
consisted of hospital clinic patients whose use of oral 
contraceptives may not have been representative of 
the population from which cases were selected.
Except for the above report which included 
both CSCCs and BCSCs, only two papers to date 
 specifically have studied the association between OC 
use and CSCC (Table 1). A large  population-based 
 case-control study117 found that OC users had a 1.6 
adjusted OR for CSCC (95% CI = 1.0–2.5). ORs also 
were higher among women who last used OCs $25 
years before diagnosis (OR = 2.1, 95% CI = 1.2–3.7), 
and  within-group ORs increased with duration of use 
[OR for # 2 years, 1.7 (95% CI = 0.9–3.5); OR for 
3–6 years, 2.6 (95% CI = 1.0–6.5); OR for $ 7 years, Ta
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2.7 (95% CI = 0.9–8.5); Ptrend = 0.01]. Among women 
who had used OCs for $25 years, those with no vari-
ant alleles for the XPD Lys751 Gln DNA repair gene 
(which is responsible for repairing  UVR-induced DNA 
lesions) had a 4.4-fold greater OR (95% CI = 1.4–13.6) 
for CSCC than women with $1 variant alleles. A simi-
lar increased risk with OC use was obseved in a nested 
case-control study using a large retrospective cohort 
of Kaiser Permanente  Northern California members.42 
In this study, pre-diagnostic OC use was associated 
with a 2.4-fold OR (95% CI = 1.2–4.8) for CSCC 
in univariate analyses and with borderline statisti-
cal significance in multivariable analysis (OR = 2.0, 
95% CI = 0.91–4.5). The multivariable risk likely was 
artifactually decreased in part due to over adjustment 
by variables associated with OC use but not with the 
outcome of CSCC. Information was not collected to 
assess a dose-response effect. A pooled effect anal-
ysis of the two studies yielded ORpooled = 1.7 (95% 
CI = 1.1–2.5).179,180 Neither study adjusted for sexual 
behavior or presence of HPV.
3.2 Strength of the evidence
The propensity of OC use to increase risk for specific 
cancers in humans, including CSCC, remains uncer-
tain due to various methodologic concerns.121,125,131,132 
For example, the frequent use of analgesics among 
women (aspirin, nonaspirin NSAIDs, and acetamino-
phen) is known to be inversely associated with con-
centrations of estrogen (estradiol, Ptrend = 0.001; free 
estradiol, Ptrend = 0.01; estrone sulfate, Ptrend = 0.03; 
ratio of estradiol to testosterone, Ptrend = 0.04) and 
could have confounded the results of studies that did 
not account for this variable when examining the asso-
ciation between OC use and cancer.133  Certain antibi-
otics, anticonvulsants (except sodium valproate), and 
vitamin C similarly are known to interact with OCs.134 
Furthermore, changes over time in the formulation of 
OCs (eg, typical estrogen doses in the 1960s were 
more than twice the typical doses in the 1980s and 
since) must be considered when evaluating OC use 
and cancer risk.135,136 Additional research is needed to 
determine whether OC use increases risk for CSCC 
among individuals with a specific hormone receptor 
profile, analogous to the increased risk for triple-neg-
ative breast cancer patients.
Although estrogen and progesterone receptors are 
present in normal skin,137,138 CSCCs are not thought 
to express significant amounts of sex hormones139 
and thus OCs probably do not significantly influence 
CSCC risk through sex hormone pathways.140 How-
ever, OCs may operate through a non-sex hormone 
pathway such as p53.140 Inactivation of the p53 gene is 
believed to play a pivotal gatekeeper role in SCC car-
cinogenesis, and estrogen appears to inhibit the actions 
of this tumor suppressor.141 Estrogen also is believed 
to exert an antiapoptotic effect on cell growth through 
the activation of signaling pathways such as Src/Shc/
ERK.138 In contrast, risk for CSCC is increased in ova-
riectomized Ptch1+/− and Car-S mice,142 while the inci-
dence of CSCC is lower in women than men.41,81
The lack of a direct carcinogenic effect of OC use 
on CSCC does not rule out an interactive effect with 
another carcinogen such as HPV. Longterm OC use 
has been shown to enhance HPV transcription in cer-
vical intraepithelial neoplasia and it could have a sim-
ilar effect on development in CSCC.121,143 OC use also 
could be non-causally associated with CSCC through 
increased sexual activity and exposure to HPV.
4. Human Papillomavirus Virus
4.1 Description and overview
HPV is a short sequence (eg, 7200 to 8000 base pairs 
of closed-circular double-stranded DNA of approxi-
mately 8 kbp), epitheliotropic, nonenveloped DNA 
virus that belongs to the papovaviridae family of 
viruses.144 Over the 30 years since the first types were 
isolated,145 approximately 118 papillomavirus (PV) 
types have been identified, and nearly 100 are known 
to infect humans.146 Current data support the existence 
of more than 200 HPV types based on the detection 
of subgenomic amplicons.146–148 The papilloma fam-
ily of viruses is classified into 8 genera identified by 
Greek letters (alpha, beta, gamma, delta, kappa, mu, 
nu, xi), of which only two do not contain HPV types 
(delta, kappa).147 Genera and species containing cuta-
neous HPV types include alpha (species 4, 8), beta 
(species 1), gamma (species 1), mu (species 1, 2), and 
nu (species 1).147 Beta-PV types [previously referred 
to as epidermodysplasia verruciform (EV) types] thus 
far fully sequenced include 5, 8, 9, 12, 14, 15, 17, 
19–25, 36–38, 47, 49, 75, 76, 80, 92, 93, and 96.149 
All HPVs contain at least seven early genes (E1–E7), 
two late genes (L1–L2), and an upstream regulatory 
region that control most transcriptional events of the 
HPV genome.150 Evidence of an oncogenic role for 
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papilloma virus in CSCCs was first found in a study 
of Shope papilloma virus, which causes skin papillo-
mas in rabbits.151,152 Treatment of skin with a chemi-
cal co-carcinogen frequently induced transformation 
of rabbit papillomas into CSCC. However, animal 
PVs are not known to infect humans, as is the case 
for some other viruses like influenza, HIV-1, Ebola, 
or SARS.147
CSCCs mainly have been associated with beta- and 
gamma-PVs,75 although alpha-PVs usually linked with 
anogenital SCCs are found in SCCs of the hand, fin-
ger, nail, and toe.5,153–173 Except in immunosuppressed 
patients or individuals with the hereditary disorder 
EV, beta- and gamma-papillomaviruses normally 
are associated only with asymptomatic infections.147 
Although beta- and gamma-PVs are widespread, they 
contain many HPV types that remain to be sequenced 
and formally described.147 Some novel cutaneous 
types such as HPV-109 have an uncertain classifica-
tion because of an equal similarity in the L1 gene to 
different genera.174
Intermediate-risk
HPV-31 (?), 33, 35, 39,
45 (?), 51, 52, 56–59, 61
Established HPV – related neoplasms
(Anal, cervical, tonsillar)
Low-risk
HPV-6, 11, 13, 32, 34,
40, 42, 44, 53, 54, 55, 63
High-risk
HPV-16, 18
High-risk
Beta HPV-5, 8; species 2
Uncertain-risk
Alpha—HPVs
CSCC Intermediate-risk
Beta-HPV-14, 17, 20, 47
Figure 2. HPv types and cancer risk.
Note: In contrast to anal, cervical and tonsillar cancers, the role for alpha HPvs remain uncertain for most CSCCs.
Virtually 100% of the population is exposed to one 
or more HPV types in their lifetime,175,176 and most 
individuals will not develop skin or other cancers 
potentially associated with the virus. Although a broad 
spectrum of HPV types frequently are detected in nor-
mal skin175,177–179 and actinic keratoses (AK),180 this fact 
does not preclude a pathogenic role in skin cancer since 
the presence of the virus should precede tumor devel-
opment.17 Similarly, a large portion of the population 
has been exposed to the ubiquitous Epstein-Barr virus 
and do not develop nasopharyngeal carcinoma, even 
though the virus is a well established risk factor for the 
cancer.175 HPV is more frequently found on the fore-
head than on less sun exposed areas such as the thighs, 
possibly indicating a role for local photoimmunosup-
pression in the colonization of cutaneous HPV.180
The oncogenic potential of specific HPV types has 
been based primarily on data from anogenital and oral 
cavity SCCs and their precursor lesions (Fig. 2). HPV 
types 16 and 18 have a high risk for malignant progres-
sion, while HPV types 31, 33, 35, 39, 45, 51, 52, 56–59, 
OC use/HPv infection and squamous cell skin cancer
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and 61 have been traditionally categorized as having 
intermediate risk of progression.181,182 The inclusion of 
HPV 31 and HPV 45 into the intermediate group likely 
will be readdressed in the future. Benign lesions typi-
cally harbor HPV types 6, 11, 13, 32, 34, 40, 42, 44, 
53, 54, 55, and 63,181,182 although some benign types 
have been implicated in SCCs outside of the anogeni-
tal region (eg, oral cavity cancer183 and paranasal sinus 
dysplasia184). Supposedly benign non-genital warts 
containing HPV-1 also have been reported to manifest 
Bowenoid histologic features185 and they appear capa-
ble of converting to CSCC under the influence of UVR 
and immunosuppression.186 HPV-2, which is classically 
associated with palmoplantar warts, has been found in 
verrucous carcinoma of the foot.187 Many of the virus 
types detected in the anogenital tract are seen in both 
squamous intraepithelial lesions (carcinoma in situ) and 
invasive squamous cell cancers of the skin, albeit with 
different frequencies and risk distributions. Other HPV 
types are unique to the skin.78,188–190 High risk mucosal 
types found in CSCCs include HPV−16, −18, −51, −54, 
−56, −61, and −69.189,191,192 Among OTRs, low risk HPV 
types 6 and 11 are frequently found in benign, prema-
lignant, and malignant cutaneous lesions.192 Mixed type 
HPV infections within a single lesion are commonly 
observed in immunosuppressed patients, but less fre-
quently in CSCCs in the general population.78
Oncogenic HPV types are believed to promote tumor 
progression by expressing E6/E7 viral  oncoproteins. 
These proteins act on cyclins E and A to stimulate 
cell proliferation,181 disrupt the p53-mediated cellular 
response to DNA damage, and induce the degradation 
of the retinoblastoma tumor suppressor gene product 
(pRB) through the proteasome.193–195 HPV-16 DNA is 
capable of integrating into the genome of epithelial 
tumor cells and altering transcription, as shown by 
the expression of E6 and E7 in derived cell lines.196 
Immortalized human keratinocytes created in the labo-
ratory by injecting DNA from HPV into the cells have 
been shown to become tumorigenic after chronic expo-
sure to benzo(a)pyrene.197 High levels of E6/E7 protein 
expressed by HPV-16 stimulate apoptosis though the 
release of IL-1α from keratinocyte cell cultures.198
Studies of E6 in cutaneous beta HPVs indicate 
that this protein gene product has the potential for 
oncogenic transformation, though to a considerably 
lesser degree than high risk alpha-HPV types, and 
transformation probably depends on interaction with 
other co-carcinogens to cause mutations in the host 
cell genome.181 For example, the expression of the 
HPV-8 E6 open reading frame (ORF) is able to induce 
morphologic transformation in rodent fibroblasts but 
lacks the capability to transform NIH 3T3 cells or 
human keratinocytes in vitro as shown for high-risk 
HPV-16 and HPV-18.76,199,200 Morphologic transfor-
mation in a rat fibroblast cell line, 3Y1, also has been 
observed for the E6 gene of HPVs 5, 8, 47, and less 
potently for HPVs 14, 20, 21, and 25.201 The E6 pro-
tein consists of five regions delimited by two zinc-
finger domains, the second of which is believed to 
be the key transforming element.201,202 Several cutane-
ous HPV types produce E6 proteins, which have been 
shown to induce apoptosis in response to UVR dam-
age in tissue culture experiments.203–205 At the same 
time, a p53-independent pathway for HPV viral onco-
proteins capable of inducing mutations206 and inter-
rupting apoptosis in response to DNA damage207,208 
may play a role in a subset of HPV-related cancers.209 
Interestingly, E6 proteins of HPV-1, HPV-8, and 
HPV-16, but not HPV-6, have been shown to bind 
to XRCC1 (a polypeptide implicated in the repair of 
various DNA single-strand breaks) and impair single-
strand break repair.210
HPVs reside ubiquitously, often in a latent state, 
in the skin and mucosal epithelia.146,181,211,212 A specific 
trophic affinity is seen for squamous epithelial cells 
at specific sites in which the complete replicative 
life-cycle of HPV is limited to this cell type.150,213,214 
HPV infection and related neoplasms occur at 
greater than expected rates in individuals who are 
immunosuppressed,215–223 suggesting that impaired 
cell-mediated immunity, whether of iatrogenic origin, 
or related to HIV infection and/or other causes, plays 
an important role in the early transition from latency 
to the overt presentation of HPV-related disease.218 
Evidence suggests that late-stage cancer invasion is 
not greatly influenced by immune status,224 and other 
factors such as genetic change may be more directly 
involved in the later progression from high-grade 
HPV-related disease to cancer.181,216–218,225,226
4.2 Route of transmission
Most studies suggest a positive association between 
sexual behavior (eg, young age at first intercourse, 
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high lifetime number of sexual partners, sex with 
non-monogamous partners, and other sexually trans-
mitted infections) and HPV infection in anogenital 
disease.211,227–237 A higher than expected concordance 
of HPV infection in sexual partners also suggests 
venereal transmission.238–242 HPV is spread in a non-
hematogenous fashion (eg, infection primarily occurs 
at sites where the virus enters the body such as the 
genital tract, skin, and oral cavity) without a viremic 
phase, and probably is clinically significant as a con-
sequence of ongoing sexual behaviors and persistent 
re-infection.219,243–246
Horizontal skin-to-skin contact in humans has 
been documented in several reports, however ques-
tions remain regarding whether the infection is 
largely transient and non-productive.143 The pres-
ence of HPV alone does not necessarily imply 
 infection.143 In one study, the detection of same types 
of HPV on the female hand and the male genitals 
of heterosexual couples suggested hand carriage as a 
pathway for HPV infection.247 Couples experiencing 
HPV transmission in this study were more sexually 
active and were more likely to use nonbarrier forms 
of  contraception. Male self-inoculation also was 
observed to occur and was attributed to casual con-
tact or masturbation. The feasibility of HPV trans-
mission through sex related skin-to-skin contact also 
was demonstrated in a cross-sectional study which 
found that co-habiting partners of the opposite-sex 
shared a greater number of beta-PV types than either 
shared with randomly selected matched members of 
the population.248 Among participants in this study 
with at least one virus infection (26 couples), 74% 
of the partners and 46% of the control pairs shared 
at least one type (P = 0.02). In another study, trans-
mission of beta-PV between individuals who were 
living in close proximity (but were not sexually inti-
mate) was rare; suggesting that casual contact alone 
probably is insufficient for infection in most cases.179 
Surprisingly, genital examinations of patients with 
digital CSCC and of their spouses have not revealed 
simultaneous genital SCC lesions.249 However, a his-
tory of a genital SCC successfully treated many years 
prior to the diagnosis of a digital SCC (both lesions 
revealed the same oncogenic HPV subtype)  suggests 
that a very long delay may intervene between a 
genital SCC and a subsequent HPV-related digital 
CSCC.169,173,249
The isolation of HPV DNA in fomites on equipment 
after examination of patients with genital HPV infec-
tions provides further evidence that high-risk genital 
HPV can survive outside the mucosal environment and 
may even be transmitted through sex toys and massage 
instruments.250 Samples collected from the bedroom 
floor of infected individuals also have tested positive 
for HPV DNA.277 Further research is needed to deter-
mine whether horizontal transmission of HPV between 
sexual partners through intimate skin-to-skin contact 
(with or without penis penetration) is possible and 
represents a clinically meaningful source of infection.
4.3 HPv persistence and clearance
Very little is currently known about either the per-
sistence or clearance of HPV infection in the skin. 
However, in the anogenital area, where the persis-
tence of HPV infection is believed to be an impor-
tant prerequisite for the development of most cervical 
intraepithelial neoplasias and cancers,242,243,251–253 HPV 
type 16 [relative risk (RR) = 0.47, 95% CI = 0.32–
0.72], and to a lesser degree types 31, 33, 35, 52, 
58) (RR = 0.62, 95% CI = 0.47–0.94), were observed 
to have a lower clearance rate than low risk types.245 
This finding also has been noted in several previous 
studies.244,246,254–259 In one study, infection with single 
and multiple HPV types had similar clearance rates, 
eg, type-specific HPV clearance was independent of 
co-infection with other types.245 However, in another 
study, HPV persistence was associated with multiple 
HPV types.257 A dose-response relationship between 
viral load and persistence of HPV infection has been 
found in some244,260 but not all studies.245
Genital HPV-16 infection typically clears within 
2 years if an intact immune response is present (eg, fully 
functioning T helper/inducer, Langerhans, and natu-
ral killer cells).233,244,245,257,261,262 In fact, less than half 
of HPV infections persist 6 months.245 Some studies 
indicate that HPV infection has a greater tendency to 
persist in older women which may be explained by 
hormonal changes and/or lifestyle differences among 
older women,245,261 or reactivation of latent disease in 
some women as they age and their immune surveil-
lance diminishes.263 However, other studies have not 
observed an older age effect for HPV infection.264–266 
Among women 20–29 years old, younger age was a 
risk factor for oncogenic HPV infection.267 In a large 
population-based cohort analysis, determinants of 
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HPV-16 seropersistence included having one sexual 
partner during the follow-up period and former oral 
contraceptive use.264 A 14-fold estimated risk for cer-
vical cancer was observed for women who had at 
least three positive tests for high-risk HPV than for 
those who had negative results.258
In constrast to genital HPV, the acquisition of cuta-
neous HPV appears to first occur in early infancy, 
posing an inherent obstacle to effective vaccine 
development.268,269 This also suggests other means of 
spread than sexual. Specific HPV types may persist in 
normal skin269,270 or benign skin lesions271 over long 
periods of time. Approximately half (48%) of healthy 
individuals have been found positive for the same 
cutaneous HPV type after 6 years of  follow-up.272 
Also, beta-PV type specific persistence in plucked 
eyebrow hairs was observed over a period of at least 
6 months in 74% of the participants examined in a 
2-year follow-up study of healthy adults.179 Similarly, 
30% of the total beta-PV detected 7 years earlier in 
hair samples was found to persist at later follow-up.149 
DNA from multiple beta-PV also has been detected in 
follow-up at 6 months or longer.179
The presence of an endogenous reservoir for HPV 
is believed to be an an important factor underlying 
the persistence of this virus. In the anogenital and 
oral cavities, the mucosal environment appears to 
serve as a receptive reservoir for HPV infection. The 
lack of a similar mucosal reservoir for the skin sug-
gests that HPV may not play a role in the etiology of 
CSCC comparable to that in anogential or oral can-
cer.  However, hair follicles may act as a possible res-
ervoir for cutaneous HPV, based on the high number 
of samples testing positive for the virus17,273–275 and 
the concurrence of same type HPV-positive pairs in 
skin cancer biopsies and plucked eyebrow hairs.276 
Also, in hair samples obtained from the head region, 
HPV typing has revealed the presence of multiple 
HPV types, including those associated with genital 
infection.17
4.4 epidemiologic evidence of HPv  
in CSCC
In contrast to the role of high-risk HPV types in ano-
genital cancers, the epidemiologic data to date do not 
support a neccessary role for these HPV types in CSCC, 
given the large number of negative cases. The ubiq-
uitous presence of cutaneous HPV in non-cancerous 
skin176,177,270,272,277,278 and the long-lasting HPV warts 
observed in transplant recipients11 further indicate that 
skin-borne HPV infection is not an absolute cause of 
CSCC. Rather, risk appears to involve an interaction 
between other carcinogens (eg, sunlight, immunosup-
pression, chemicals, hormones, and radon), race, and 
genetic factors. For example, a statistically significant 
relationship has been observed between increased 
time spent outdoors and detection of HPV in healthy 
skin.278 Similarly, HPV DNA was significantly asso-
ciated with sites extensively exposed to the sun, in 
both lesions and healthy skin samples.279 However, 
one study found no convincing evidence of an asso-
ciation between beta- or gamma-PV seroprevalence 
and measures of sun sensitivity or UV exposure.280 
Evidence of a supportive rather than a direct role for 
cutaneous HPV types in CSCC also is shown by the 
difficulty of obtaining positive cell lines for these 
HPV types, the inability of these viruses to immortal-
ize human cells and degrade p53, and the relatively 
low number of viral genomes detected per cancer 
cell.17,181,281,282 Although integrated beta-PV has been 
isolated from a metastasic CSCC in an OTR, most of 
the evidence suggests that beta-PV is episomal in both 
AK and CSCC.175,283 However, integration of HPV 
DNA into host chromosomal DNA is not absolutely 
required for malignant transformation to occur as has 
been obseved by  Sánchez-Lanier and colleagues.155 
It remains to be determined whether HPV has a non 
passenger role in the etiology of CSCC.284 In con-
strast, HPV related cancers of the anogenital track 
meet the epidemiologic, molecular, and functional 
criteria of the World Health Organization (WHO) for 
viral  carcinogenesis.284 Three types of epidemiologic 
research described below provide support for the role 
of HPV in the etiology of CSCC.
4.4.1 epidermodysplasia verruciforms (ev)
A link between beta-PVs and CSCC was first observed 
in patients with the rare inherited disorder EV, which is 
characterized by a defect in cell-mediated  immunity.285 
In this condition, individuals develop persistent viral 
warts at a young age (eg, 4–8 years) on UVR-exposed 
areas of the body that progess in about 30% of cases to 
CSCC during middle age.178,286 EV related CSCCs test 
positive for HPV-5 and −8 in 90% of cases287 and for 
HPV-14, −17, −20, and −47 less frequently.76,287 The 
HPV types found in  EV-related skin cancers also are 
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detected in approximately 80% of CSCCs of OTRs,288 
but CSCCs of OTRs typically have lower viral loads 
than the CSCCs of non-OTRs.190,284,289 Oddly, anti-
bodies against EV-HPV are not common in the north-
ern European population.75 EV-HPV DNA has been 
shown to be transcriptionally active in some CSCCs, 
indicating that EV-HPV may contribute directly to the 
pathogenesis of CSCC.70 However, to date it has not 
been possible to demonstrate in vitro transformation 
of human keratinocytes using EV-HPV or the forma-
tion of tumors in nude mice by EV-HPV-8 E6 trans-
formed fibroblasts.78,200 Occassionally, p53-positive 
EV tumors have been observed in nonexposed skin, 
suggesting that factors other than UVR exposure may 
play a role in this cancer.285
4.4.2 Organ transplant recepients
A double-digit or greater increased relative risk for 
CSCCs among iatrogenic immunosuppressed OTRs 
has been observed in several studies.12,284,290–294 And 
risk appears to be greater for specific immunosuppres-
sive regimens.295,296 The tumors occur on average 6 to 
7 years following transplantation and typically appear 
on sun-exposed sites.76 Up to 70% of OTRs experi-
ence a NMSC by 20 years after transplantation, and 
the majority are CSCCs.290,297 Most CSCCs are char-
acterized by multiple types of HPV infection.78 While 
EV-HPV is the predominant type found in this malig-
nancy, cutaneous HPV types are found in approxi-
mately 50% of lesions, and less frequently, mucosal 
HPV types (,15%).78 While premalignant skin lesions 
and viral warts are highly prevalent in HPV infec-
tion and might indirectly suggest progression from 
less dysplastic forms to invasive CSCC,78,190,298,299 it 
should be noted that the distribution of HPV types 
in viral warts generally differs from that observed in 
precancers or CSCCs.297 Although OTRs receive bet-
ter than average clinical follow-up, surveillance bias 
alone probably does not explain the 250 times higher 
incidence of CSCC among OTRs than in the general 
population.291
4.4.3 Association studies
In contrast to the widely accepted epidemiologic 
 evidence linking high-risk HPVs to cervical cancer, the 
role of HPV in CSCC remains unclear. A  retrospective 
study of immunocompetent participants, controlling 
for age, sex, and sun exposure to the head, face, neck, 
forearm, hands, and lower limbs observed a 32-fold 
greater OR (95% CI = 10–100) for CSCC among those 
testing positive for DNA HPV than for those testing 
negative.297 A 59-fold adjusted OR (95% CI = 5.4–645) 
for NMSC was reported for the subset of cases testing 
positive for high-risk HPV mucosal types (16, 31, 33, 
35, and 51). An adjusted OR was not reported, but the 
crude OR for CSCC among those testing positive for 
high-risk HPV mucosal types was 31 (95% CI = 3.8–
258). The prevalence of HPV infection in normal skin 
was low (4.7%), however, compared with a previous 
report,178 suggesting that ORs in this study may have 
been inflated. Furthermore, the percentage of mucosal 
types detected on the hands/fingers versus other sites 
was not specified in the study. HPV-16 is rarely found 
in non-genital, nondigital, CSCCs in healthy immu-
nocompetent individuals.249,300 In another case-control 
study of immunocompetent individuals, DNA from 
beta-PV species 2 was found more frequently in 
CSCC than in adjacent healthy skin (OR = 4.0, 95% 
CI = 1.3–12), indicating a possible differential risk by 
specific beta-HPV types.301 The results of this study are 
difficult to interpret, however, since 1) in situ hybrid-
ization to determine viral load was not performed, and 
2) tissue samples apparently were not “stripped” to 
reduce surface contamination.302 The significant dif-
ferences also may have been attributable to chance 
since results were not adjusted for numerous (.45) 
multiple comparisons. Nonetheless, the findings were 
similar to those of a previous study which observed a 
4.40 OR (95% CI = 1.92–10.06) for CSCC in associa-
tion with beta-PV species 2.279 Neither of the above 
two studies addressed the possibility that the differen-
tially greater prevalence of beta-PV infection was the 
result of changes to the immune system caused by the 
cancer.
Several association studies which tested for beta-PV 
antibody positivity have found an increased risk for 
CSCC,60,303–305 and risk was greater in the presence 
of a susceptible phenotype (gender, skin color, pro-
pensity to burn) or high lifetime sun exposure.304,305 
No difference in HPV seropositivity has been found 
between BCSC patients and controls.304 The increased 
risk for CSCC does not necessarily imply causality 
since it is not possible to determine the origin of HPV 
infection (eg, skin, oral cavity, anogenital area) or the 
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exact timing of infection when using antibody testing. 
Given the ubiquity of the virus and the relatively low 
number of seropositives, the majority of antibodies 
directed at HPV probably are generated near the time 
of tumor formation, suggesting reverse causality.303 
Furthermore, not all infected women test positive for 
antibodies against HPV, due in part to the extended 
period necessary for the immune system to produce 
these proteins, or to the lack of a sustained antigenic 
exposure and/or a low viral load.306–308  Positive asso-
ciations for CSCC have been reported when using 
a degenerate and nested polymerase chain reaction 
(PCR) technique to assess HPV positivity in normal 
skin309 or plucked eyebrow hairs.310 However, the 
concordance between specific HPV types in normal 
and proliferative lesions from the same individual 
was low.309 Overall, PCR results must be interpreted 
cautiously since HPV detection by this method is not 
necessarily equivalent to infection with HPV188 and 
alternatively could be a contamination or a passerby. 
PCR also does not provide information about the 
intracellular localization of viral DNA.17
Allograft recipients are especially susceptible 
to NMSCs and anogenital dysplasia/cancer,299 rais-
ing the question of whether HPV is a possible com-
mon risk factor in both diseases. For example, renal 
allograft recipients (RARs) classified with $4 intra-
epidermal carcinomas (IECs) or invasive CSCCs 
have been found significantly more likely to develop 
potentially life-threatening multiple anogenital tract 
neoplasms than less susceptible RARs (,4 IECs or 
CSCCs).211 Similarly, in the general population an 
increased risk for CSCC has been observed after 
anogenital cancer, and conversely, an increased risk 
of anogenital cancers has been observed follow-
ing CSCC, although risk estimates varied widely 
by histologic category and gender.112–114,312,313 For 
example, a 20-fold standardized incidence ratio 
(SIR) for CSCC has been observed following anal 
cancer among women during the first year of fol-
low-up, but not among men.112 The increased risk 
of non-Hodgkin’s lymphoma observed following 
CSCC appears to indicate that immune suppression, 
rather than HPV, is the mechanism underlying both 
cancers, since HPV is not known to be a risk factor 
for non-Hodgkin’s lymphoma.314 Exposure to UVR 
has been suggested as a common risk factor because 
of its effects on the immune system and the similar 
temporal trends and geographic patterns that exist 
for non-Hodgkin’s lymphoma and CSCC.97
4.5 Strength of the evidence
Proof that HPV infection is causally related to CSCC 
awaits definitive laboratory and epidemiologic 
confirmation.188,315 A consistent understanding of 
cutaneous HPV infection and CSCC risk is lacking 
largely because of methodological difficulties in HPV 
detection and reproducibility.309 The interpretation of 
results is further complicated by the so-called “hit 
and run” hypothesis, according to which HPV may be 
important only for the initiation, not the maintenance 
of the transformed cellular phenotype.175,288,316 Indeed, 
the number of beta-PV genome copies per tumor cell 
in AK (the precursor lesion of CSCC) is approximately 
10-fold higher than in CSCC.74,175,317 This raises the 
question of an etiologic role for HPV even though the 
resulting CSCCs lack HPV viral genes or proteins.318 
Nonetheless, no cutaneous “high-risk” HPV types on 
par with genital HPVs have been identified.279 Nor 
has any beta-PV type been shown to cause CSCC in 
experimental systems,149 although in one study 6% (9 
cases) of backcrossed mice, transgenic for the HPV-8 
early region under control of the keratin 14 promoter, 
spontaneously developed invasive SCC appearing 
lesions without any treatment with physical or chem-
ical carcinogens.319,320 Furthermore, the detection of 
beta-PV in CSCC, in the absence of other evidence, 
does not prove causation. For example, beta-PV may 
occur as a consequence of immunosuppression, simi-
lar to other non-oncogenic opportunistic infections 
(eg, cytomegalovirus, herpes simplex virus, mollus-
sum contagiosum, aspergillosis, and candidiasis).
The mechanism by which HPV causes CSCC, 
if that is the case, would appear to differ from that 
of other known HPV-related neoplasms. In the case 
of the cervix, anus, and tonsils, HPV tends to cause 
cancer in “transformation zones” where one kind 
of epithelium transitions within a defined boundary 
into another type of epithelium through a process 
known as metaplasia (eg, columnar epithelium into 
squamous epithelium).321 A comparable transforma-
tion zone does not exist for exposed skin, with the 
exception of the eyelids, lips, and periungual region. 
Furthermore, oncogenic genital HPV types are able 
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to bind to and degrade p53 through the proteasome in 
contrast to cutaneous HPV types.203,322,323
5. Interactions between OCs and HPV
Much of the work on the possible effects of estro-
gen and OCs on HPV prevalence has focused on the 
inflammatory and immune regulatory properties of 
this hormone in the uterus.324 Response variations in 
these properties are thought to be important determi-
nants of the viral persistence and progression underly-
ing the development of SCC.325,326 Estrogen is known 
to cause an influx of neutrophils and macrophages, 
tissue edema, and proliferation of uterine epithe-
lial cells.324 Additionally, OCs alter the expression 
of certain regulatory cytokines, such as IL-10 and 
IL-12, in the cervical mucous.325 Results reflect the 
 down-regulation of immune markers in the cervix, 
corresponding to changes in reproductive hormones 
observed in animals during the menstrual cycle.327 
Overall though, reproductive hormones appear to 
enhance immunity.327,328
A consistent picture has yet to emerge  regarding 
the influence of OCs on HPV infection and the subse-
quent development of SCCs. In a pooled case-control 
study of cervical cancer, neither OC use nor  increasing 
dose was significantly associated with HPV positivity 
among controls, suggesting that OCs do not have a 
facilitating role in HPV infection or persistence.329 
Indeed, current use of OCs had a  significantly 
 protective effect on the follow-up incidence of HPV 
[hazard ratio (HR) = 0.49, 95% CI = 0.28–0.86].330 
Similarly, in a study of atypical squamous cells of 
undetermined significance (ASCUS), oncogenic HPV 
was less common in women who were using oral 
contraceptives, although the difference was not sta-
tistically significant (P = 0.15).331 In a crude analysis, 
approximately 35% of current OC users, compared 
with 26% of referents, were identified with prevalent 
cervicovaginal HPV (OR = 1.52, 95% CI = 1.03–232); 
however, the difference was not statistically signifi-
cant after adjustment for various demographic, sexual, 
and lifestyle factors.232 Similarily, positive univari-
able but null multivariable results were observed in 
an analysis of the third National Health and Nutrition 
Examination Survey (NHANES III).332 Three addi-
tional studies have not observed a statistically signifi-
cant association between cervical HPV infection and 
OC use.230,231,237
In constrast, increased prevalence of HPV is seen 
in the lower genital tract of pregnant women.333 After 
adjusting for age, number of lifetime and recent sex-
ual partners, age at first intercourse, and smoking, 
former OC use (OR = 1.3, 95% CI = 1.1–1.5) and 
current OC use (OR = 1.5, 95% CI = 1.2–1.8) were 
associated with HPV-16 seropositivity in a large 
population-based cohort of 10,000 women in Costa 
Rica.334 Regardless of duration, OC use [0 years, 
OR = 1.0; 1 year, OR = 2.2 (95% CI = 1.2–4.0); 
2–3 years, OR = 2.1 (95% CI = 1.2–3.9); 4+ years, 
OR = 2.5 (95% CI = 1.2–5.1)] was associated with 
HPV infection (specific types not specified), inde-
pendent of age, race, and lifetime number of male 
sexual partners.228 When examined by HPV type, OC 
use was significantly associated with increased detec-
tion of HPV-16/18 (P = 0.04).335 Inexplicably, OC use 
appeared to decrease the risk of low grade squamous 
intraepithelial lesions whether women were positive 
or negative for HPV infection.335 These discrepant 
findings, however, may be attributable to differences 
in study design, sampling strategies, and varying sen-
sitivity, specificity, and accuracy of HPV detection 
methods.232
Supporting the role of estrogen in the malignant 
transformation of HPV infected cells into SCC, a 
 laboratory study has demonstrated that estrogen 
stimulates the differential transcription of the E6/E7 
and E1 genes of HPV-16 in SiHA cervical carcinoma 
cells.336 Glucocorticoids, a class of compounds resem-
bling the steroids found in OCs,335 also have been shown 
to enhance the transformation of HPV-16 infected 
cell lines and increase the in vitro transcription and 
expression of the HPV-16 genome.337–339
Estrogen-induced squamous cell carcinogenesis 
has been demonstated in the female reproductive tract 
of K14-HPV-16 transgenic mice;340 and β-oestradiol 
has been shown to stimulate the in vivo growth of 
human condylomas induced with HPV in mice.336 
The possibility also exists that reproductive hormones 
may promote the integration of HPV DNA into the 
host genome,341 which would be consistent with the 
observed increased risk for cervical cancer after pro-
longed use of OC.329
Conclusion
The evidence to date does not support an independent 
or synergistic role for OC use in the development of 
OC use/HPv infection and squamous cell skin cancer
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CSCC; nor does it fail to do so. Proof of association 
does not, of course, indicate a cause-and-effect rela-
tionship, as illustrated by the association between 
herpes genitalis and cervical carcinoma.316,342 Many 
questions remain to be answered. OC use may sim-
ply be a surrogate marker for sexual activity343,344 
and non-causally associated with CSCC risk through 
increased exposure to HPV. This depends on whether 
HPV is a causative factor in CSCC, which remains 
controversial.315 On the other hand, OCs may have 
a contributing biologic role in the cascade of events 
leading up to CSCC. For example, certain beta-PV 
types in combination with OC use may play an 
initiation role, while the promotion or progression of 
CSCC ultimately depends on UVR exposure.61 The 
period between a hormonal exposure and the appear-
ance of cancer may be lengthy, as illustrated by the 
development of vaginal cancer in daughters years after 
their mothers used diethylstilbestrol (DES) during 
pregnancy.345 Notably, the above initiation/promotion 
model does not explain the occurrence of CSCC on 
predominantly non sun-exposed skin, suggesting 
that factors other than UVR also may be important 
promoters in the development of this cancer. CSCCs 
remain a major public health concern, ranking among 
the most prevalent and costliest cancers in the United 
States and serving as an important harbinger of sec-
ondary malignancies.346–348
The incidence of nonmelanoma skin cancer (in 
which CSCC is an important subtype) has approxi-
mately doubled since the mid 1990’s.349 Future large-
scale studies that incorporate detailed epidemiologic 
information (eg, OC use, sexual history, molecular 
markers, and exposure to UVR, chemicals and HPV) 
and provide analyses stratified by in situ and invasive 
CSCCs and tumor location are needed to help unravel 
the complex picture of this disease.
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